JP2018501216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501216A5 JP2018501216A5 JP2017529360A JP2017529360A JP2018501216A5 JP 2018501216 A5 JP2018501216 A5 JP 2018501216A5 JP 2017529360 A JP2017529360 A JP 2017529360A JP 2017529360 A JP2017529360 A JP 2017529360A JP 2018501216 A5 JP2018501216 A5 JP 2018501216A5
- Authority
- JP
- Japan
- Prior art keywords
- cornea
- cross
- composition
- light
- applying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 12
- 210000004087 Cornea Anatomy 0.000 claims 7
- 239000000654 additive Substances 0.000 claims 6
- 229910052742 iron Inorganic materials 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000000996 additive Effects 0.000 claims 4
- 239000007979 citrate buffer Substances 0.000 claims 4
- 239000003431 cross linking reagent Substances 0.000 claims 4
- 238000004132 cross linking Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 229960002477 Riboflavin Drugs 0.000 claims 2
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 235000019192 riboflavin Nutrition 0.000 claims 2
- 239000002151 riboflavin Substances 0.000 claims 2
- 230000002186 photoactivation Effects 0.000 claims 1
Claims (10)
- 以下を含む、眼の角膜へ処置を適用するための組成物：
光活性化光への曝露に応答して角膜で架橋活性を生成する架橋剤；
鉄添加物；及び
クエン酸緩衝液。 - 架橋剤がリボフラビンを含む、請求項１に記載の組成物。
- 鉄添加物がＦｅＳＯ４を含む、請求項１に記載の組成物。
- 鉄添加物がクエン酸緩衝液に溶解される、請求項１に記載の組成物。
- 光活性化光が紫外線である、請求項１に記載の組成物。
- 以下を含む、眼の角膜へ処置を適用するための方法：
以下を含む組成物を角膜へ適用すること：
光活性化光への曝露に応答して角膜で架橋活性を生成する架橋剤；
鉄添加物；及び
クエン酸緩衝液；
光活性化光を角膜に適用して、角膜で架橋活性を生成すること。 - 架橋剤がリボフラビンを含む、請求項６に記載の方法。
- 鉄添加物がＦｅＳＯ４を含む、請求項６に記載の方法。
- 鉄添加物がクエン酸緩衝液に溶解される、請求項６に記載の方法。
- 選択された濃度の酸素を眼に適用することをさらに含み、選択された濃度が大気中の酸素の濃度より大きい、請求項６に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086572P | 2014-12-02 | 2014-12-02 | |
| US62/086,572 | 2014-12-02 | ||
| PCT/US2015/063466 WO2016090016A1 (en) | 2014-12-02 | 2015-12-02 | Systems, methods, and compositions for cross-linking treatments of an eye |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501216A JP2018501216A (ja) | 2018-01-18 |
| JP2018501216A5 true JP2018501216A5 (ja) | 2018-03-15 |
| JP6674462B2 JP6674462B2 (ja) | 2020-04-01 |
Family
ID=56092400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529360A Active JP6674462B2 (ja) | 2014-12-02 | 2015-12-02 | 眼の架橋処置のためのシステム、方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160175442A1 (ja) |
| EP (2) | EP4082547A1 (ja) |
| JP (1) | JP6674462B2 (ja) |
| KR (1) | KR102606740B1 (ja) |
| CN (1) | CN107206003B (ja) |
| WO (1) | WO2016090016A1 (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110237999A1 (en) | 2010-03-19 | 2011-09-29 | Avedro Inc. | Systems and methods for applying and monitoring eye therapy |
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| WO2012167260A2 (en) | 2011-06-02 | 2012-12-06 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| JP6644799B2 (ja) | 2014-10-27 | 2020-02-12 | アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． | 眼の架橋処置のためのシステム及び方法 |
| WO2016077747A1 (en) | 2014-11-13 | 2016-05-19 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
| EP3827792A1 (en) | 2015-04-24 | 2021-06-02 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| EP3297589A4 (en) | 2015-05-22 | 2019-03-06 | Avedro Inc. | SYSTEMS AND METHOD FOR MONITORING THE NETWORKING ACTIVITY FOR CORNEAL TREATMENTS |
| JP6933377B2 (ja) | 2015-07-21 | 2021-09-08 | アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． | 光増感剤を用いた眼の処置用システム及び方法 |
| WO2017180851A1 (en) | 2016-04-13 | 2017-10-19 | Avedro, Inc. | Systems and methods for delivering drugs to an eye |
| US10932864B2 (en) | 2018-11-28 | 2021-03-02 | Rxsight, Inc. | Tracking-based illumination control system |
| US11013593B2 (en) | 2018-12-02 | 2021-05-25 | Rxsight, Inc. | Light adjustable lens tracking system and method |
| JP2022514127A (ja) * | 2018-12-04 | 2022-02-09 | アヴェドロ インコーポレイテッド | 眼の治療のための化合物および組成物 |
| US20220106298A1 (en) * | 2019-01-25 | 2022-04-07 | Avedro, Inc. | Bis(diazirine) derivatives as photo-crossslinker for treating corneal ectatic disorders |
| KR102234258B1 (ko) * | 2019-01-28 | 2021-03-31 | 경북대학교 산학협력단 | 안압이 상승된 동물 모델, 그의 제조방법 및 그를 이용한 녹내장 치료제의 스크리닝 방법 |
| CN114848817A (zh) * | 2019-05-17 | 2022-08-05 | 北京厚燊维康科技有限责任公司 | 二酮类化合物在光动力治疗或诊断中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153582A (en) * | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
| FR2849383B1 (fr) * | 2002-12-26 | 2005-09-30 | Jean Noel Thorel | Composition trophique en milieu aqueux, et ses applications, notamment en ophtalmologie |
| MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| US9707126B2 (en) | 2009-10-21 | 2017-07-18 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
| WO2011050164A1 (en) | 2009-10-21 | 2011-04-28 | Avedro, Inc. | Eye therapy |
| US20130245536A1 (en) | 2009-10-21 | 2013-09-19 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
| US20110237999A1 (en) | 2010-03-19 | 2011-09-29 | Avedro Inc. | Systems and methods for applying and monitoring eye therapy |
| US20120215155A1 (en) | 2010-03-19 | 2012-08-23 | Avedro Inc. | Controlled cross-linking initiation and corneal topography feedback systems for directing cross-linking |
| ES2590127T3 (es) * | 2011-01-12 | 2016-11-18 | Sooft Italia S.P.A. | Administración corneal de agentes de entrecruzamiento por iontoforesis para el tratamiento de queratocono y composiciones oftálmicas relacionadas |
| WO2014189849A1 (en) * | 2013-05-19 | 2014-11-27 | Avedro, Inc. | Systems, methods, and compositions for cross-linking |
-
2015
- 2015-12-02 KR KR1020177017789A patent/KR102606740B1/ko active IP Right Grant
- 2015-12-02 JP JP2017529360A patent/JP6674462B2/ja active Active
- 2015-12-02 EP EP22178453.1A patent/EP4082547A1/en active Pending
- 2015-12-02 US US14/957,187 patent/US20160175442A1/en not_active Abandoned
- 2015-12-02 EP EP15864372.6A patent/EP3226871B1/en active Active
- 2015-12-02 WO PCT/US2015/063466 patent/WO2016090016A1/en active Application Filing
- 2015-12-02 CN CN201580074913.0A patent/CN107206003B/zh active Active
-
2019
- 2019-10-16 US US16/655,208 patent/US20200046835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501216A5 (ja) | ||
| JOP20190042B1 (ar) | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل | |
| MX2017013983A (es) | Uso de agentes activos durante tratamientos quimicos. | |
| JP2019526543A5 (ja) | ||
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| CY1122805T1 (el) | Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| WO2018128678A3 (en) | Compositions and methods for restructuring chemically treated hair | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| MX2018013663A (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| BR112019001457A2 (pt) | tratamento e prevenção de distúrbios do sono | |
| MX2018013973A (es) | Metodos de tratamiento de sindromes de comportamiento usando pipradrol. | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| EA201690997A1 (ru) | Композиция для применения в лечении стойкого кашля | |
| EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| EA201991570A1 (ru) | Амидные соединения и их применение | |
| MX370061B (es) | Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. | |
| BR112018076935A2 (pt) | composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia | |
| EA201692196A1 (ru) | Применение 1,3-пропандисульфоновой кислоты или ее фармацевтически приемлемых солей для лечения саркоидоза | |
| ZA202001258B (en) | Methods of using dantrolene to treat nerve agent exposure | |
| MX2016009226A (es) | Combinaciones farmaceuticas. |